SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila receives final approval from USFDA for Indomethacin Capsules

27 Sep 2017 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Indomethacin Extended-Release Capsules USP, 75 mg. The drug is indicated for use in painful and inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute painful shoulder (bursitis and/or tendinitis).

The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 155 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.



Zydus Lifesciences Share Price

941.50 -1.05 (-0.11%)
20-Apr-2026 10:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1671.00
Dr. Reddys Lab 1236.40
Cipla 1238.15
Zydus Lifesciences 941.50
Lupin 2330.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×